Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid leukemia (AML). Howev...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Schmalbrock, Laura K., Dolnik, Anna, Cocciardi, Sibylle, Sträng, Eric, Theis, Frauke, Jahn, Nikolaus, Panina, Ekaterina, Blätte, Tamara J., Herzig, Julia, Skambraks, Sabrina, Rücker, Frank G., Gaidzik, Verena I., Paschka, Peter, Fiedler, Walter, Salih, Helmut R., Wulf, Gerald, Schroeder, Thomas, Lübbert, Michael, Schlenk, Richard F., Thol, Felicitas, Heuser, Michael, Larson, Richard A., Ganser, Arnold, Stunnenberg, Hendrik G., Minucci, Saverio, Stone, Richard M., Bloomfield, Clara D., Döhner, Hartmut, Döhner, Konstanze, Bullinger, Lars
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2021
Témata:
Myeloid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8233666/
https://ncbi.nlm.nih.gov/pubmed/33598693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007626
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky